Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
:GH
GH Analyst Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GH Stock 12 Month Forecast
Average Price Target
$62.73
▲(14.49% Upside)
| Highest Price Target$70.00 | Average Price Target$62.73 | Lowest Price Target$56.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Barclays
$60
Buy
9.51%
Upside
Reiterated
09/05/25
Bank of America Securities
$60→$65
Buy
18.63%
Upside
Reiterated
09/04/25
Evercore ISI
$60
Buy
9.51%
Upside
Reiterated
09/04/25
Canaccord Genuity
$65
Buy
18.63%
Upside
Reiterated
09/04/25
Raymond James
$59→$61
Buy
11.33%
Upside
Reiterated
09/04/25
Leerink Partners
$70
Buy
27.76%
Upside
Reiterated
09/04/25
BTIG
$65→$70
Buy
27.76%
Upside
Reiterated
09/04/25
Guardant Health: Strong Market Position and Optimistic Outlook with Raised Price TargetWe are pleased to see that Guardant demonstrated a 1-point improvement in overall sensitivity, and a significant 7-point improvement on stage 1 sensitivity, at the same level of specificity. We were hoping to see some, or any, improvement as a positive, and we believe today's update is a nice advancement of the company's leadership position in blood based testing. We have long regarded Guardant as the pioneer and market leader in liquid biopsy, so today's news further builds on our view. GH remains our and shares are up 96% YTD. As for why the stock is down 9% today, we think this does not make sense, and remind our readers that most investors and other analysts overreacted and misinterpreted GH's first ECLIPSE data readout as "terrible", which it was not.
TR | OpenAI - 4o
$46→$62
Hold
13.16%
Upside
Reiterated
08/19/25
AI Generated ArticleAI Generated Article
TD Cowen
$63
Buy
14.98%
Upside
Reiterated
08/07/25
Piper Sandler
$60
Buy
9.51%
Upside
Reiterated
08/04/25
William Blair
―
Buy
―
Reiterated
07/31/25
Guardant Health's Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay ConcernsWe believe this underlying strength should result in shares being able to at least hold the current multiple over the next 12 months, and our initial review of the model shows there is still likely upside that can come. This view on the model and sustainability of heightened growth rates—especially in the oncology business—underpins our Outperform rating and we see no reason to move away from that following the print.
Mizuho Securities
―
Buy
―
Reiterated
07/31/25
Scotiabank
$57→$60
Buy
9.51%
Upside
Reiterated
07/31/25
Guggenheim
$56
Buy
2.21%
Upside
Reiterated
07/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
$60
Buy
9.51%
Upside
Reiterated
09/05/25
Bank of America Securities
$60→$65
Buy
18.63%
Upside
Reiterated
09/04/25
Evercore ISI
$60
Buy
9.51%
Upside
Reiterated
09/04/25
Canaccord Genuity
$65
Buy
18.63%
Upside
Reiterated
09/04/25
Raymond James
$59→$61
Buy
11.33%
Upside
Reiterated
09/04/25
Leerink Partners
$70
Buy
27.76%
Upside
Reiterated
09/04/25
BTIG
$65→$70
Buy
27.76%
Upside
Reiterated
09/04/25
Guardant Health: Strong Market Position and Optimistic Outlook with Raised Price TargetWe are pleased to see that Guardant demonstrated a 1-point improvement in overall sensitivity, and a significant 7-point improvement on stage 1 sensitivity, at the same level of specificity. We were hoping to see some, or any, improvement as a positive, and we believe today's update is a nice advancement of the company's leadership position in blood based testing. We have long regarded Guardant as the pioneer and market leader in liquid biopsy, so today's news further builds on our view. GH remains our and shares are up 96% YTD. As for why the stock is down 9% today, we think this does not make sense, and remind our readers that most investors and other analysts overreacted and misinterpreted GH's first ECLIPSE data readout as "terrible", which it was not.
TR | OpenAI - 4o
$46→$62
Hold
13.16%
Upside
Reiterated
08/19/25
AI Generated ArticleAI Generated Article
TD Cowen
$63
Buy
14.98%
Upside
Reiterated
08/07/25
Piper Sandler
$60
Buy
9.51%
Upside
Reiterated
08/04/25
William Blair
―
Buy
―
Reiterated
07/31/25
Guardant Health's Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay ConcernsWe believe this underlying strength should result in shares being able to at least hold the current multiple over the next 12 months, and our initial review of the model shows there is still likely upside that can come. This view on the model and sustainability of heightened growth rates—especially in the oncology business—underpins our Outperform rating and we see no reason to move away from that following the print.
Mizuho Securities
―
Buy
―
Reiterated
07/31/25
Scotiabank
$57→$60
Buy
9.51%
Upside
Reiterated
07/31/25
Guggenheim
$56
Buy
2.21%
Upside
Reiterated
07/30/25
Best Analysts Covering Guardant Health
1 Month
xxx
Success Rate
10/18 ratings generated profit
Average Return
+6.69%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +6.69% per trade.
3 Months
xxx
Success Rate
9/16 ratings generated profit
Average Return
+10.79%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +10.79% per trade.
1 Year
Success Rate
13/16 ratings generated profit
Average Return
+48.86%
reiterated a buy rating last month
Copying David Westenberg's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +48.86% per trade.
2 Years
xxx
Success Rate
14/16 ratings generated profit
Average Return
+88.75%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +88.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GH Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
1
2
3
2
Buy
35
30
32
20
19
Hold
5
8
5
6
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
39
39
29
24
Each month's total comprises the sum of three months' worth of ratings.
GH Financial Forecast
GH Stock Forecast FAQ
What is GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is 62.73.
What is GH’s upside potential, based on the analysts’ average price target?
Guardant Health has 14.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GH a Buy, Sell or Hold?
Guardant Health has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Guardant Health’s price target?
The average price target for Guardant Health is 62.73. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $56.00. The average price target represents 14.49% Increase from the current price of $54.79.
The highest analyst price target is $70.00 ,the lowest forecast is $56.00. The average price target represents 14.49% Increase from the current price of $54.79.
What do analysts say about Guardant Health?
Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of GH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.